Qatar Metabolomics Study on Diabetes

The Qatar Metabolomics Study on Diabetes (QMDiab) is a type 2 diabetes case-control, which was conducted in 2012 at the Dermatology Department of Hamad Medical Corporation and the Weill Cornell Medical College in Doha, Qatar. The study was approved by the Institutional Review Boards of HMC and WCM-Q under research protocol number 11131/11. All study participants provided written informed consent.<br><br>Untargeted metabolomics measurements (LC/MS+, LC/MS-, and GC/MS) from plasma, urine, and saliva samples of 374 participants, which are aged 17-81 years, were performed by Metabolon Inc.<br><br>The OrigScale dataset comprises median-scaled data for each body fluid. The Preprocessed dataset comprises missing values treated, normalized, transformed, and scaled data. In both datasets, rows correspond to participants (anonymized) and columns correspond to metabolites. <br><br>Phenotype information (type 2 diabetes status, age, gender, BMI, ethnicity) are available as the last six columns of each dataset.<br>Annotations and pathway assigments are also provided for each metabolite.